Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
复制标题
DOI：
10.1161/01.cir.0000141573.44737.5a
复制
发表时间：
2004-09-14
期刊：
影响因子：
37.8
通讯作者：
Wachtell, K
中科院分区：
文献类型：
--
作者：
Devereux, RB;Dahlöf, B;Wachtell, K
背景-氯沙坦干预降低高血压终点（LIFE）试验的超声心动图子研究旨在测试氯沙坦比阿替洛尔更能降低左心室（LV）质量的能力。方法和结果-在7个国家的研究中心共招募了960名患有原发性高血压和LV肥大（LVH）的患者，2、3、4和5年随机治疗。临床检查和超声心动图的盲法读数在457例氯沙坦治疗和459例阿替洛尔治疗的参与者中进行，随访测量的LV质量指数（LVMI）大于或等于1，用于意向治疗分析。在调整基线LVMI、血压和治疗中血压后，氯沙坦治疗组LVMI较阿替洛尔组降低幅度更大（-21.7+/-21.8 vs-17.7+/-19.6 g/m2; P=0.021）。在女性和男性中观察到氯沙坦更大的LVMI降低，参与者>65岁或
Background-An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol.Methods and Results-A total of 960 patients with essential hypertension and LV hypertrophy (LVH) on screening ECG were enrolled at centers in 7 countries and studied by echocardiography at baseline and after 1, 2, 3, 4, and 5 years' randomized therapy. Clinical examination and blinded readings of echocardiograms in 457 losartan-treated and 459 atenolol-treated participants with greater than or equal to1 follow-up measurement of LV mass index (LVMI) were used in an intention-to-treat analysis. Losartan-based therapy induced greater reduction in LVMI from baseline to the last available study than atenolol with adjustment for baseline LVMI and blood pressure and in-treatment pressure (-21.7+/-21.8 versus -17.7+/-19.6 g/m(2); P=0.021). Greater LVMI reduction with losartan was observed in women and men, participants >65 or